Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neostigmine dosing for reversal of mild cisatracurium-induced neuromuscular blockade
ChiCTR2500109352Phase 4Not yet recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of neostigmine in neuromuscular block (NMB) (4 arms), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Neuromuscular recovery time to TOFr 0.9. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
neostigmine
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on ChiCTR2500109352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109352.